BioNexus Gene Lab Corp. issued a press release detailing progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia. The announcement follows a working visit by Fidelion Diagnostics’ Chief Commercial Officer to Tongshu Gene facilities in Shanghai and Changzhou, China, where the platform is in paid commercial use. BioNexus holds exclusive rights to the platform in ten Southeast Asian markets and owns approximately 15% of Fidelion. The company targets initial deployment in Malaysia and Singapore during 2026, pending regulatory approvals and laboratory validation. BioNexus Gene Lab Corp. operates in the biotechnology and precision diagnostics industry, developing healthcare technologies and specialty materials.